ERBB2 and gastroesophageal junction adenocarcinoma: PD-L1 CPS ≥ 1, HER2 negative, untreated, locally advanced, unresectable, or metastatic G/GEJ adenocarcinoma. 72.6% male, median age 62 years, 48% ECOG 0, 57.8% from Europe/North America/Australia, 24.2% from Asia, and 18.0% from other regions.